The lab-on-chip technology aims
to replace huge laboratories; © PHIL
All modules for sample preprocessing and detection are ready for further miniaturization and integration in a single lab-on-chip platform.
In case of breast cancer, five millilitres of blood contains only two to three tumor cells. To detect cancer from blood, these rare circulating tumor cells need to be isolated, enriched and their genetic content has to be identified.
Current diagnostics performed in medical laboratories are labor intensive, expensive and time-consuming. They require many sample preprocessing steps in different medical instruments so that the full analysis takes more than a day. A lab-on-chip system enables a fast, easy-to-use, cost-effective test method which can be performed at regular times in a doctor’s office or even near the patient’s bed.
The project partners developed a modular platform where each module has its specific task and autonomy and as such can also be used for many different medical applications. The first module is the incubation module performing the mixing of the blood sample with functionalized magnetic beads which specifically bind the tumor cells. The second module is used for tumor cell isolation and counting using a combination of dielectrophoresis and magnetic sensing with single cell sensitivity. In the third module, the amplification module, the cell wall of the tumor cells is destroyed and the genetic material (i.e. the mRNA) is extracted and amplified based on multiplex ligation dependent probe amplification (MLPA).
Within this module, specific assays amplify about 20 markers that are expressed in breast carcinoma cells. In the final detection module, the amplified genetic material is detected using an array of electrochemical sensors. The different building blocks have been developed and validated on spiked blood samples. The modules are now ready for further hetero-integration into a single lab-on-chip. By miniaturizing and merging the microfluidic and electronic functionalities the reliability and accuracy of the patient’s analysis will be improved. The clinical use of the system will be evaluated to compare it to more conventional approaches in a breast cancer therapy follow-up study in Oslo.
COMPAMED.de; Source: Interuniversity Microelectronics Centre (IMEC)